tiprankstipranks
Paradigm Biopharmaceuticals Ltd. (AU:PAR)
ASX:PAR
Australian Market

Paradigm Biopharmaceuticals Ltd. (PAR) Financial Statements

Compare
22 Followers

Paradigm Biopharmaceuticals Ltd. Financial Overview

Paradigm Biopharmaceuticals Ltd.'s market cap is currently $218.08M. The company's EPS TTM is AU$-0.191; its P/E ratio is ―; Paradigm Biopharmaceuticals Ltd. is scheduled to report earnings on February 19, 2025, and the estimated EPS forecast is AU$―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Jun 23Jun 22Jun 21Jun 20
Income Statement
Total RevenueAU$ 65.80KAU$ 46.76KAU$ 79.22KAU$ 20.55KAU$ 0.00
Gross ProfitAU$ 56.81KAU$ -125.72KAU$ -257.78KAU$ -288.65KAU$ -213.12K
Operating IncomeAU$ -65.11MAU$ -59.22MAU$ -47.01MAU$ -42.34MAU$ -16.96M
EBITDAAU$ -64.54MAU$ -59.06MAU$ -46.82MAU$ -42.13MAU$ -15.70M
Net IncomeAU$ -58.65MAU$ -51.91MAU$ -39.25MAU$ -34.30MAU$ -12.30M
Balance Sheet
Cash & Short-Term InvestmentsAU$ 17.87MAU$ 56.38MAU$ 39.72MAU$ 71.08MAU$ 104.67M
Total AssetsAU$ 27.39MAU$ 67.07MAU$ 50.69MAU$ 84.79MAU$ 112.36M
Total DebtAU$ 239.33KAU$ 341.67KAU$ 616.67KAU$ 751.84KAU$ 873.69K
Net DebtAU$ -17.58MAU$ -55.99MAU$ -39.06MAU$ -70.28MAU$ -103.05M
Total LiabilitiesAU$ 3.58MAU$ 13.39MAU$ 8.38MAU$ 6.52MAU$ 4.18M
Stockholders' EquityAU$ 23.81MAU$ 53.68MAU$ 42.31MAU$ 78.27MAU$ 108.18M
Cash Flow
Free Cash FlowAU$ -65.94MAU$ -45.19MAU$ -32.21MAU$ -34.96MAU$ -10.22M
Operating Cash FlowAU$ -65.94MAU$ -45.19MAU$ -32.21MAU$ -34.93MAU$ -10.09M
Investing Cash FlowAU$ 0.00AU$ 0.00AU$ 1.00AU$ 668.37KAU$ 5.62M
Financing Cash FlowAU$ 28.18MAU$ 62.53MAU$ 70.12KAU$ 1.00MAU$ 36.05M
Currency in AUD

Paradigm Biopharmaceuticals Ltd. Earnings and Revenue History

Paradigm Biopharmaceuticals Ltd. Debt to Assets

Paradigm Biopharmaceuticals Ltd. Cash Flow

Paradigm Biopharmaceuticals Ltd. Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis